您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Myristyl nicotinate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Myristyl nicotinate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Myristyl nicotinate图片
CAS NO:273203-62-6
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
100mg电议
200mg电议
500mg电议

产品介绍
Myristyl nicotinate (Tetradecyl nicotinate) 是一种酯前药和 Nicotinic acid 的亲脂衍生物。Myristyl nicotinate 被开发用于将烟酸输送到皮肤中,以防止光化性角化病及其发展为皮肤癌。Myristyl nicotinate 显示刺激光损伤的皮肤中的表皮分化,增加皮肤 NAD 含量并增强人皮肤屏障。
Cas No.273203-62-6
别名肉豆蔻醇烟酸酯,Tetradecyl nicotinate
Canonical SMILESO=C(C1=CC=CN=C1)OCCCCCCCCCCCCCC
分子式C20H33NO2
分子量319.48
溶解度DMSO: 9.62 mg/mL (30.11 mM)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Myristyl nicotinate (Tetradecyl nicotinate) is an ester prodrug and a lipophilic derivative of Nicotinic acid. Myristyl nicotinate is being developed for delivery of Nicotinic acid into the skin for prevention of actinic keratosis and its progression to skin cancer. Myristyl nicotinate shows to stimulate epidermal differentiation in photodamaged skin, increasing skin NAD content and strengthening the skin barrier[1][2].

Myristyl nicotinate (Tetradecyl nicotinate) is used for treatment and prevention of conditions that involve skin barrier impairment such as chronic photodamage and atopic dermatitis or for mitigating skin barrier impairment that results from therapy such as retinoids or steroids[2].

[1]. Catz P, et al. Simultaneous determination of myristyl nicotinate, nicotinic acid, and nicotinamide in rabbit plasma by liquid chromatography-tandem mass spectrometry using methyl ethyl ketone as a deproteinization solvent. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Dec 27;829(1-2):123-35. [2]. Jacobson MK, et al. Effect of myristyl nicotinate on retinoic acid therapy for facial photodamage. Exp Dermatol. 2007 Nov;16(11):927-35.